Home / Stocks / Haleos Labs Limited
HALEOSLABS

Haleos Labs Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,580.5

Change

-51.9 (-3.18%)

Open

₹1,632.4

Prev. Close

₹1,632.4

Day High

₹1,639.3

Day Low

₹1,570.0

Volume Analysis

Traded

594

Delivered

459

Delivery %

77.27%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (1)

  • •Low return on equity (8.44%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,692.5 ₹1,665.9 ₹1,623.2 ₹1,596.6 ₹1,553.9 ₹1,527.3 ₹1,484.6
Fibonacci ₹1,665.9 ₹1,639.43 ₹1,623.07 ₹1,596.6 ₹1,570.13 ₹1,553.77 ₹1,527.3
Camarilla ₹1,599.56 ₹1,593.21 ₹1,586.85 ₹1,596.6 ₹1,574.15 ₹1,567.8 ₹1,561.44

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+20.65%

1 Week

-0.85%

1 Month

-0.21%

3 Months

+7.88%

6 Months

-4.72%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹592.22

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

7.94%

Net margin 3.29% × asset turnover 1.2x × equity multiplier 2.01x

Company Overview

Sector

Healthcare

Market Cap

₹494 Cr

P/E (TTM)

38.1

ROE

8.44%

Book Value

₹725.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Haleos Labs Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 52/100. The strongest factor is Financial Strength (81/100), while Institutional Ownership (30/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (8.44%).

TopFund Score — Fundamentals Quality

52/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

81

Growth

32

Valuation

34

Cash Flow

38

Corporate Governance

71

Momentum

79

Institutional Ownership

30

Business Quality

46

Risk & Volatility

66

Liquidity

50

From Screener.in

  • −The company has delivered a poor sales growth of 4.68% over past five years.
  • −Company has a low return on equity of 8.23% over last 3 years.
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Enclosed - Newspaper advertisement for Q2F27 (results)

Haleos Labs withholds FY26 dividend for shareholders with incomplete KYC or incorrect bank details.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 69 72 90 93 78 85 89 83 81 95 75 73 91
Expenses + 61 63 79 76 70 72 82 71 68 81 71 64 83
Operating Profit 8 9 11 16 9 13 7 12 14 14 4 9 8
OPM % 11.45% 12.91% 12.62% 17.59% 10.92% 15.07% 8.33% 14.19% 16.69% 14.82% 5.54% 12.5% 9.1%
Other Income + 0 1 2 0 2 0 2 1 0 0 2 0 0
Interest 3 2 3 2 2 2 2 2 2 2 1 2 2
Depreciation 4 4 4 4 4 4 4 4 4 4 4 4 4
Profit before tax 2 4 7 11 5 7 4 7 8 9 1 3 2
Tax % 126.51% -8.14% 8.73% 33.27% 29.72% 29.81% 11.45% 37.61% 24.38% 24.26% 62.22% 46.51% 12.5%
Net Profit + 0 4 6 7 3 5 3 4 6 7 0 2 2
EPS in Rs 2 14 20 23 15 18 10 14 20 22 1 9 11
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -15 -18 41 24 13 17 -1 -11 4 12 -16 -12 12

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 0 0 218 213 378 261 266 350 316 306 345 334 334
Expenses + 0 0 189 200 343 235 235 316 287 275 300 289 299
Operating Profit 0 0 28 13 35 25 30 35 29 31 45 45 36
OPM % — — 13.0% 6.0% 9.0% 10.0% 11.0% 10.0% 9.0% 10.0% 13.0% 13.0% 11.0%
Other Income + 0 0 2 3 2 2 2 14 5 4 5 2 3
Interest 0 0 6 4 6 5 5 6 7 10 9 7 7
Depreciation 0 0 6 6 6 8 8 10 11 15 15 15 16
Profit before tax 0 0 18 6 25 15 20 33 17 10 26 25 15
Tax % — — 30.0% -2.0% 30.0% 31.0% 31.0% 23.0% 31.0% 36.0% 28.0% 29.0% —
Net Profit + 0 0 13 6 18 10 14 25 11 6 19 18 11
EPS in Rs — — — 22 59 34 45 84 38 30 67 57 43
Dividend Payout % — — 0.0% 0.0% 3.0% 0.0% 3.0% 2.0% 4.0% 5.0% 2.0% 3.0% —
Sales growth — — — -2 — -31 2 32 -10 -3 13 -3 -1

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 0 0 82 85 103 113 126 149 166 174 194 211 216
Borrowings + 0 0 26 27 47 65 65 80 100 101 86 111 135
Other Liabilities + 0 0 67 61 116 72 108 125 126 114 107 130 146
Total Liabilities 0 0 175 177 270 253 302 357 395 391 390 454 500
Fixed Assets + 0 0 73 69 118 124 130 142 228 223 232 268 259
CWIP 0 0 0 7 3 16 38 51 1 6 0 10 30
Investments 0 0 0 5 0 0 0 0 0 0 0 0 0
Other Assets + 0 0 102 95 148 113 134 164 166 162 158 176 210
Total Assets 0 0 175 177 270 253 302 357 395 391 390 454 500
Equity Capital 0 0 0 3 3 3 3 3 3 3 3 3 3

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 0 0 20 8 30 15 35 -11 15 24 34 37
Cash from Investing Activity + 0 0 -8 -7 -44 -27 -26 -7 -31 -18 -15 -58
Cash from Financing Activity + 0 0 -12 -1 15 12 -3 11 17 -7 -19 21
Net Cash Flow 0 0 0 0 1 0 6 -8 0 -1 0 1
Free Cash Flow 0 0 12 4 6 -9 0 -53 -28 4 19 -21
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit — — 87 66 105 69 133 -10 62 88 94 98

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 70.68% → 72.1%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 29.31% 28.81% 28.59% 28.57% 28.59% 28.6% 28.56% 28.57% 27.91% 27.59% 27.58% 27.58%
Promoters 70.68% 71.19% 71.4% 71.4% 71.4% 71.4% 71.4% 71.4% 71.79% 72.1% 72.1% 72.1%
FII 0.0% 0.0% 0.01% 0.02% 0.0% 0.0% 0.03% 0.0% 0.0% 0.0% 0.0% 0.0%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.03% 0.29% 0.3% 0.31% 0.31%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Haleos Labs Limited (this stock) 494 38.1 2.25 8.44%
Valiant Laboratories Ltd 570 35.2 1.72 -2.55%
Medicamen Biotech Limited 407 35.2 1.39 3.95%
Fabtech Technologies Ltd 609 20.5 1.39 12.0%
Rays Of Belief Limited 615 99.3 4.03 16.1%
Qms Medical Allied S Ltd 336 31.3 3.23 10.4%
Lyka Labs Ltd. 328 — 3.39 -10.2%

Which Mutual Funds Hold Haleos Labs Limited?

Frequently Asked Questions about Haleos Labs Limited

Community Sentiment

What are other investors saying about Haleos Labs Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.